The international surgical journal with global reach

Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810-821

Published: 29th April 2020

Authors: Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J et al.

Conclusion

A total of 602 women took part in the first interim analysis. Complete pathological response was 64.8 per cent with additional pembrolizumab, compared to 51.2 per cent in women having standard neoadjuvant chemotherapy (p<0.001).

Pubmed Link